The mechanism difference, plainly
Both are engineered gut-hormone mimics. Semaglutide is a GLP-1 receptor agonist: it slows stomach emptying, prompts insulin when glucose is high, and reduces appetite signalling. Tirzepatide does all of that and additionally activates the GIP receptor – a second incretin pathway. The working theory is that dual activation affects appetite and metabolism through more than one route at once.
What the trials actually showed
In SURMOUNT-1, tirzepatide produced average weight reduction of roughly 15 to 21 percent across doses over 72 weeks. In STEP-1, semaglutide 2.4 mg produced roughly 15 percent over 68 weeks. In SURPASS-2, a direct head-to-head in type 2 diabetes, tirzepatide outperformed semaglutide 1 mg on both glucose control and weight. Different trials, different populations – which is why 'tirzepatide is stronger on average' is a fair summary and 'tirzepatide is better for you' is not.
Side effects: same family, similar pattern
Both are dominated by digestive effects – nausea, diarrhea, constipation, indigestion – clustering around dose increases and easing as the body adjusts. Both carry a boxed warning about thyroid C-cell tumors seen in rodents. Some people tolerate one noticeably better than the other, and that is a legitimate reason to switch.
Trial results belong to the specific FDA-approved product studied, at the doses studied.
Practical differences that decide it
Both are weekly injections with monthly titration. Brand availability, insurance coverage, savings programs, and cash pricing differ and change over time. Oral formulations exist for semaglutide (see the oral semaglutide guide), which matters if needles are the obstacle. Your diagnosis governs which approved product applies – Wegovy and Zepbound for weight management, Ozempic and Mounjaro for type 2 diabetes.
How the decision actually gets made
Not by a table. A clinician reviews your history, medications, prior response, tolerability, and goals, then chooses – and may determine that neither is appropriate. Starting on the 'stronger' molecule is not automatically the better plan if you cannot tolerate the titration. See the 30-second film answers for this medication.
How tirzepatide works on two receptors at once
Tirzepatide is a single molecule that activates two incretin receptors: GIP and GLP-1. Both are receptors your gut already uses. After a meal, the intestine releases incretin hormones that tell the pancreas to release insulin, slow how fast the stomach empties, and signal fullness to the hypothalamus. Tirzepatide binds those same receptors, so the signal is present at a steadier level than it would be from food alone. The GLP-1 arm is the one most people have heard of. The GIP arm is what distinguishes tirzepatide from semaglutide, which acts on GLP-1 only. According to the FDA prescribing information for tirzepatide products, dual agonism is the mechanism of record. What that difference means for any individual is a clinical question, not a settled one, and a licensed clinician decides whether the medication is appropriate for you at all.
A compounded preparation is not a generic of, or equivalent to, any FDA-approved product.
What compounded means, and what it does not
A compounded preparation is made by a licensed pharmacy for an individual patient on receipt of a valid prescription. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. That is a statement about regulatory pathway, not an accusation about any particular pharmacy, and it is why the distinction matters more than marketing language does. A compounded preparation is not a generic and not an equivalent of any FDA-approved brand product. Published clinical trials such as SURMOUNT-1 studied the branded product at studied doses; those findings should not be assumed to transfer. What compounded means unpacks the legal framework, and red flags when buying online covers how to tell a legitimate pharmacy from a grey-market seller.
Why side effects are mostly digestive, and mostly early
Because the receptors tirzepatide acts on sit in the gut and the brainstem, the predictable effects are digestive: nausea, reflux, constipation, diarrhoea, and a feeling of fullness that arrives sooner than expected. According to FDA prescribing information for tirzepatide products, gastrointestinal reactions are the most commonly reported adverse events, and they are dose-related for many people. The practical implication is that they tend to cluster around a dose change rather than persist indefinitely. Serious risks are listed separately in the label, including pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumours in rodents. Those are not common, but they are the reason the medication is prescription-only. Report severe or persistent abdominal pain, vomiting that stops you keeping fluids down, or vision changes to your clinician promptly rather than waiting for a scheduled check-in.
What a titration schedule is actually for
Titration means starting at a dose below the one intended to be effective and stepping up on a schedule. It exists for tolerability, not caution for its own sake. Receptor signalling that arrives gradually gives the gut time to adapt, which is why the label sets minimum intervals between increases rather than leaving the pace open. Skipping ahead does not accelerate anything except side effects. Holding at a dose is a legitimate clinical decision, and so is stepping back down. If you want the lower end of that range as a deliberate plan rather than a waypoint, that is what microdosing describes. Your clinician sets the schedule, reviews how you are tolerating it, and adjusts. Nothing about a titration plan guarantees a particular result, and no schedule substitutes for the follow-up conversation that decides whether to continue.
No card needed to see it. No insurance accepted or required.
Frequently asked questions
Is tirzepatide always more effective?
On trial averages it produced greater weight reduction. Individual response varies widely at every dose, and the medicine you tolerate consistently usually beats the one you abandon.
Can I switch from one to the other?
Many people do, under clinician direction – usually for tolerability, plateau, cost, or availability. It is not a self-directed swap; dose ladders are not interchangeable.
Are compounded versions the same as the brands?
No. Compounded semaglutide and tirzepatide are prepared per prescription by licensed pharmacies, are not FDA-approved, and are not reviewed by FDA for safety, effectiveness, or quality before marketing. No equivalence to any FDA-approved product is claimed.
Which is cheaper?
It depends on brand versus compounded, insurance status, and current manufacturer programs – all of which move. Compare real monthly totals rather than list prices.
Is compounded tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved product; a compounded preparation is made by a licensed pharmacy for an individual patient and is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness, or quality before marketing, and a compounded preparation is not a generic or an equivalent.
What is the starting dose of compounded tirzepatide?
Your prescribing clinician sets the starting dose and the titration schedule, and the dispensing pharmacy supplies instructions for your specific concentration. There is no single published starting dose for compounded preparations, and units and milligrams are not interchangeable.
Let a clinician weigh the two against your history
A licensed clinician reviews your history and decides what is appropriate – which may be neither. Rx only, refunded in full if you are not prescribed.
Rx only. A licensed clinician decides whether treatment is appropriate and may determine that no treatment, or a different treatment, is right for you. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Individual results vary.
Sources
Clinical trials listed below evaluated FDA-approved products at the doses studied. They are cited as published science, not as evidence about any compounded preparation, which is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality.
- Peer-reviewedJastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216
- Peer-reviewedWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med 2021;384:989-1002
- Peer-reviewedFrías JP et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes (SURPASS-2). N Engl J Med 2021;385:503-515
- FDA databaseDrugs@FDA: search approved labeling for tirzepatide
Spotted something inaccurate? Report an error – corrections are logged per our editorial standards.
More on Compare
Same medication, different question.
